Fred King

Fred King is an experienced professional in the field of biomedical research, currently serving as the Director of Discovery Sciences at Novartis Institutes for BioMedical Research (NIBR) since September 2021. In this role, Fred leads a team focused on high throughput screening, lead compound optimization, and mechanism of action studies. Previously, as Associate Director, Fred developed and managed a screening platform utilizing large-scale, multiplexed RNA expression measurements for target validation and other applications. Fred's background includes significant roles at the Genomics Institute Of The Novartis Research Foundation, where management of the Cell Profiling Group involved extensive compound high throughput screening, and earlier positions at Novartis and Dana-Farber Cancer Institute. Fred holds a Postdoctoral Fellowship in Oncology and Cancer Biology from Harvard Medical School and a Ph.D. in Molecular Biology from Princeton University.